ES2175231T3 - Nuevas anfetaminas activadas. - Google Patents

Nuevas anfetaminas activadas.

Info

Publication number
ES2175231T3
ES2175231T3 ES97112747T ES97112747T ES2175231T3 ES 2175231 T3 ES2175231 T3 ES 2175231T3 ES 97112747 T ES97112747 T ES 97112747T ES 97112747 T ES97112747 T ES 97112747T ES 2175231 T3 ES2175231 T3 ES 2175231T3
Authority
ES
Spain
Prior art keywords
amphetamins
preparation
new activated
anphetamine
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97112747T
Other languages
English (en)
Inventor
Erasmus Dr Huber
Christian Dr Klein
Rudolf Dr Vogel
Bruno Zink
Wolfgang Dr Rollinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Application granted granted Critical
Publication of ES2175231T3 publication Critical patent/ES2175231T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/946—CNS-stimulants, e.g. cocaine, amphetamines

Abstract

LA INVENCION SE REFIERE A DERIVADOS DE ANFETAMINAS ACTIVADAS, A UN PROCEDIMIENTO PARA SU PREPARACION, ASI COMO SU USO PARA LA PREPARACION DE INMUNOGENOS QUE LLEVAN GRUPOS ANFETAMINA O CONJUGADOS DETECTABLES. OTRO OBJETO DE LA INVENCION SON NUEVOS CONJUGADOS QUE LLEVAN GRUPOS ANFETAMINA, UN PROCEDIMIENTO PARA SU PREPARACION, ASI COMO SU USO PARA LA OBTENCION DE ANTICUERPOS O PARA LA DETERMINACION DE ANFETAMINAS O DERIVADOS DE LAS MISMAS.
ES97112747T 1996-07-25 1997-07-24 Nuevas anfetaminas activadas. Expired - Lifetime ES2175231T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19630102A DE19630102A1 (de) 1996-07-25 1996-07-25 Neue aktivierte Amphetamine

Publications (1)

Publication Number Publication Date
ES2175231T3 true ES2175231T3 (es) 2002-11-16

Family

ID=7800867

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97112747T Expired - Lifetime ES2175231T3 (es) 1996-07-25 1997-07-24 Nuevas anfetaminas activadas.

Country Status (4)

Country Link
US (1) US5976812A (es)
EP (1) EP0820984B1 (es)
DE (2) DE19630102A1 (es)
ES (1) ES2175231T3 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1066523T1 (de) * 1998-03-27 2001-09-20 Microgenics Corp Kontrollbestimmungsmethoden für drogen bestehend aus kleinen molekülen
US6306616B1 (en) 1998-03-27 2001-10-23 Microgenics Corporation Adsorption type confirmatory assays
GB2361473C (en) * 2000-03-08 2005-06-28 Microgenics Corp Ecstasy-class analogs and use of same in detection of ecstasy-class compounds
WO2001081424A1 (en) * 2000-04-20 2001-11-01 The Board Of Trustees Of The University Of Arkansas Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
US7632929B2 (en) * 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
US7202348B2 (en) * 2000-04-20 2007-04-10 The University Of Arkansas For Medical Sciences Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
US6669937B2 (en) * 2000-04-20 2003-12-30 The Board Of Trustees Of The University Of Arkansas Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
US6534325B1 (en) 2000-06-30 2003-03-18 Roche Diagnostics Corporation Immunoassay for the detection of amphetamines, methamphetamines and methylenedioxy designer amphetamines
US6653456B2 (en) 2001-07-31 2003-11-25 Roche Diagnostics Corporation Site-specific aminoglycoside derivatives and their use in immunodiagnostic assays
ATE408843T1 (de) * 2001-12-20 2008-10-15 Randox Lab Ltd Verfahren und kit zum nachweis oder zur bestimmung von 3,4-methylendioxymethamphetamin
EP1331219A1 (en) * 2002-01-23 2003-07-30 Drug Abuse Sciences, Inc. New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them
US20030170917A1 (en) * 2002-03-01 2003-09-11 Roche Diagnostics Corporation Compounds, antibodies, reagent kits, methods of producing antibodies, and methods of detecting analytes
US7169907B2 (en) * 2002-03-01 2007-01-30 Roche Diagnostics Operations, Inc. Derivatives, immunogens, and antibodies for detecting ecstasy-class drugs
US7101980B2 (en) * 2002-03-01 2006-09-05 Roche Diagnostics Operations, Inc. Derivatives, conjugates, and antibodies for detecting ecstasy-class analytes
US20040242848A1 (en) * 2003-04-21 2004-12-02 Owens S. Michael Mouse/human chimeric anti-phencyclidine antibody and uses thereof
US7060847B2 (en) * 2003-07-18 2006-06-13 Roche Diagnostics Operations, Inc. Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs
US7022492B2 (en) * 2003-12-15 2006-04-04 Dade Behring Inc. Ecstasy haptens and immunogens
US20050130243A1 (en) * 2003-12-15 2005-06-16 Zheng Yi F. Assay for entactogens
US6991911B2 (en) * 2003-12-15 2006-01-31 Dade Behring Inc. Assay for entactogens
US7037669B2 (en) * 2004-03-22 2006-05-02 Dade Behring Inc. Assays for amphetamine and methamphetamine using stereospecific reagents
US7115383B2 (en) * 2004-03-22 2006-10-03 Dade Behring Inc. Assays for amphetamine and methamphetamine
AU2005309960A1 (en) * 2004-11-22 2006-06-01 Mallinckrodt Inc. Process for the purification of benzphetamine hydrochloride
US7858756B2 (en) 2006-06-15 2010-12-28 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
ES2619647T3 (es) * 2007-04-20 2017-06-26 Bioventures Llc Compuestos de hapteno y composiciones y usos de los mismos
US9023353B2 (en) 2013-03-13 2015-05-05 The Board Of Trustees Of The University Of Arkansas Anti-(+)—methamphetamine monoclonal antibodies
CN104860865B (zh) * 2015-05-28 2019-04-05 江苏省原子医学研究所 一种非典型性荧光材料琥珀酰亚胺衍生物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329281A (en) * 1978-06-05 1982-05-11 Hoffmann-La Roche Inc. Hapten compositions
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US5002883A (en) * 1987-10-30 1991-03-26 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
ATE154135T1 (de) * 1989-03-10 1997-06-15 Hoffmann La Roche Reagenzien zum nachweis von drogen
DE3919915A1 (de) * 1989-06-19 1990-12-20 Boehringer Mannheim Gmbh Aminoalkylmaleimide und davon abgeleitete hapten- und antigenderivate sowie konjugate mit peptiden oder proteinen

Also Published As

Publication number Publication date
US5976812A (en) 1999-11-02
DE59706730D1 (de) 2002-05-02
EP0820984B1 (de) 2002-03-27
EP0820984A1 (de) 1998-01-28
DE19630102A1 (de) 1998-01-29

Similar Documents

Publication Publication Date Title
ES2175231T3 (es) Nuevas anfetaminas activadas.
TR200000782T2 (tr) Resorsinol türevleri.
SV2002000249A (es) Derivados de tiazolilamida ref, lea 34082-sv
SV1996000114A (es) Nuevos plaguicidas
ES2196211T3 (es) Prepolimeros de poliuretano que presentan grupos alcoxisilano e hidantoina, un procedimiento para su preparacion asi como uso para la preparacion de materiales de sellado.
ES2098140T3 (es) Liosferas que contienen gonadotropina.
TR199701146T1 (xx) N�rotensin resept�rleri �zerinde etkili 1-Fenilpirazol-3-Karboksamidler.
HN1998000118A (es) 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
UY26451A1 (es) Procedimiento para la obtención de 1,2,3,4- tetrahidroquinolinas 4-carboxiamino-2-sustituidas
SV1999000060A (es) Procedimiento para la preparacion de (s,s)-bencil-2,8-diazabiciclo 4.3.0 nonano ref. 32965-sv
HN1997000127A (es) Procedimiento e intermedios para preparar derivados de cromanol sustituidos.
TR200102742T2 (tr) Rezorsinol türevleri
AR001813A1 (es) Derivados de cromona procedimiento para prepararlos y las composiciones farmacéutica que los contienen
ES2166045T3 (es) Procedimiento para la preparacion de compuestos de 4,6-bis(ariloxi)pirimidina asimetricos.
TR200102741T2 (tr) Resorsinol bileşimi
SV1997000010A (es) Nuevas heteroariloxazolidinonas ref. lea 31535-sv
ES2081916T3 (es) Delta-lactonas naturales y procedimiento para su fabricacion.
ES2157419T3 (es) Arilazadioxacicloalquenos substituidos, fungicidas.
CR7672A (es) Metodo microbiologico para la produccion de 11- alfa- hidroxiesteroides 7- alfa sustituidos
ES2093612T3 (es) Neoglucoproteinas, su preparacion y empleo.
ID27733A (id) Metoksiminofenilasetamida
ES2192021T3 (es) Procedimiento para preparar haluros de fenoxifenilo.
ES2116241B1 (es) Composicion para la obtencion de un aguardiente.
MX9302841A (es) Subunidades de receptores nmda, un procedimiento para su preparacion y su empleo.
ES2165512T3 (es) Feniluracilos substituidos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 820984

Country of ref document: ES